<DOC>
	<DOCNO>NCT02880631</DOCNO>
	<brief_summary>The purpose registry evaluate effect BAROSTIM THERAPY BAROSTIM NEO System commercial setting subject recently implant CE-Marked indication resistant hypertension .</brief_summary>
	<brief_title>BAROSTIM THERAPYâ„¢ In Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Has sign EC approve informed consent form Has implant BAROSTIM NEO system past 30 day Systolic blood pressure great equal 140 mmHg , Resistance maximally tolerate therapy diuretic two antihypertension medication Bilateral carotid bifurcation locate level mandible Baroreflex failure autonomic neuropathy Uncontrolled , symptomatic cardiac bradyarrhythmias Carotid atherosclerosis determine ultrasound angiographic evaluation great 50 % Ulcerative plaque carotid artery determine ultrasound angiographic evaluation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>